
ASCO 2025: Novel Bispecific T-Cell Engager Targeting DLL3 Offers Hope for Refractory Neuroendocrine Carcinomas
In a presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, Jaume Capdevila, MD, PhD, senior medical oncologist at Vall d'Hebron University Hospital in Barcelona, Spain, shared data on obrixtamig (BI 764532; Boehringer …